Utama › Masalah Mata Akibat Diabetes › California
Kajian klinikal Masalah Mata Akibat Diabetes di California
6 kajian untuk Masalah Mata Akibat Diabetes sedang mencari peserta di lokasi di California.
Bandar di California
Teks kajian rasmi (Bahasa Inggeris)
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
- Global Research Management ( Site 0066), Glendale
- Retinal Consultants Medical Group ( Site 0013), Sacramento
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 1 Okt 2026 · NCT07705555Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
- California Retina Consultants - Bakersfield /ID# 282990, Bakersfield
- Retina-Vitreous Associates Medical Group - Beverly Hills /ID# 282995, Beverly Hills
- The Retina Partners /ID# 274741, Encino
- dan 6 lagi
Mengambil pesertaFasa 2/3
Umur 18 ke atas · Semua jantina · Dikemas kini 24 Sep 2026 · NCT07592273A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7663498 Following Intravitreal Administration in Participants With Diabetic Retinopathy
- Global Research Management, Glendale
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 14 Sep 2026 · NCT07588100Village-Integrated Eye Worker Trial II
- University of California, San Francisco, San Francisco
Mengambil pesertaSukarelawan sihat dialu-alukan
Umur 60 ke atas · Semua jantina · Dikemas kini 9 Jun 2026 · NCT03752840Strategies for Improving Linkage-to-Care After Eye Disease Screening
- University of California, San Francisco, San Francisco
Mengambil peserta
Umur 60 ke atas · Semua jantina · Dikemas kini 29 Apr 2026 · NCT06943599High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
- Retina Consultants of Orange County, Fullerton
Mengambil pesertaFasa 4
Umur 21 ke atas · Semua jantina · Dikemas kini 10 Jul 2025 · NCT06662994Daripada ClinicalTrials.gov, data diperoleh pada 4 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.